Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription dug spending for children and adolescents: Increasing relevance of health economic evidence

Child and Adolescent Psychiatry and Mental Health

Volumn 1, Issue , 2007, Pages

  Schlander, Michael ^a,b,c  

^a Institute for Innovation and Valuation in Health Care (InnoValHC)   (Germany)

^b University of Applied Economic Sciences   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPROPYLBUTYLPHOSPHINIC ACID; AMPHETAMINE; ARMODAFINIL; ATOMOXETINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; LISDEXAMFETAMINE; MEDIKINET; METHYLPHENIDATE; MODAFINIL; PEMOLINE;

ADOLESCENT; ADOLESCENT HEALTH; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILD HEALTH; CHILD HEALTH CARE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG SCREENING; DRUG UTILIZATION; GERMANY; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; NATIONAL HEALTH SERVICE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOPHARMACOTHERAPY; UNITED KINGDOM;

EID: 45149092300     PISSN: None     EISSN: 17532000     Source Type: Journal    
DOI: 10.1186/1753-2000-1-13     Document Type: Article

References (97)

1. Kelleher KJ McInerny TK Gardner WP Childs GE Wasserman RC Increasing identification of psychosocial problems: 1979-1996 Pediatrics 2000, 105(6):1313-1321. 10.1542/peds.105.6.1313 10835074
2. Robison LM Sclar DA Skaer TL Galin RS National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995 Clinical Pediatrics 1999, 38(4):209-217. 10.1177/000992289903800402 10326176
3. Zito JM Safer DJ dosReis S Magder LS Gardner JF Zarin DA Psychotherapeutic medication patterns for youths with attention-deficit hyperactivity disorder Archives of Pediatrics & Adolescent Medicine 1999, 153:1257-1263. 10591302
4. Safer DJ Malever M Stimulant treatment in Maryland public schools Pediatrics 2000, 106:533-539. 10.1542/peds.106.3.533 10969099
5. Habel LA Schaefer CA Levine P Bhat AK Elliott G Treatment with stimulants among youths in a large California health plan Journal of Child and Adolescent Psychopharmacology 2005, 15(1):62-67. 10.1089/ cap.2005.15.62
6. Safer DJ Zito JM Fine EM Increased methylphenidate usage for attention-deficit disorder in the 1990s Pediatrics 1996, 98(6):1084-1088. 8951257
7. Shatin D Drinkard CR Ambulatory use of psychotropics by employer-insured children and adolescents in a national managed care organization Ambulatory Pediatrics 2002, 2(2):111-119. 10.1367/ 1539-4409(2002)002<0111:AUOPBE>2.0.CO;2 11926842
8. Lin SJ Crawford SY Lurvey PL Trend and area variation in amphetamine prescription usage among children and adolescents in Michigan Social Science & Medicine 2005, 60(3);617-626. 10.1016/ j.socscimed.2004.06.002
9. Thomas CP Conrad P Casler R Goodman E Trends in the use of psychotropic medications among adolescents, 1994-2001 Psychiatric Services 2006, 57(1):63-69. 10.1176/appi.ps.57.1.63 16399964
10. Guevara J Lozano P Wickizer T Mell L Gephart H Psychotropic medication use in a population of children who have attention-deficit hyperactivity disorder Pediatrics 2002, 109(5):733-739. 10.1542/peds.109.5.733 11986429
11. Cox ER Motheral BR Henderson RR Mager D Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: results from a commercially insured US sample Pediatrics 2003, 111:237-243. 10.1542/peds.111.2.237 12563045
12. Rowland AS Umbach DM Stallone L Naftel AJ Bohlig EM Sandler DP Prevalence of medication treatment for attention deficit-hyperactivity disorder among elementary school children in Johnston County, North Carolina American Journal of Public Health 2002, 92(2):231-234. 1447048 11818297
13. Zuvekas SH Vitiello B Norquist G Recent trends in stmulant medication among U.S. children American Journal of Psychiatry 2006, 163(4):579-585. 10.1176/appi.ajp.163.4.579 16585430
14. Medco Health Solutions Research reveals adult diagnosis of ADHD growing faster than children diagnosis Press Release September 15, 2005. http://www.epilepsy.com/ last accessed June 30, 2006.
15. Wong ICK Murray ML Camilleri-Novak D Stephens P Increased prescribing trends of paediatric psychotropic medications Archives of Disease in Childhood 2004, 89:1131-1132. 10.1136/adc.2004.050468 15557050
16. Miller AR Lalonde CE McGrail KM Armstrong RW Prescription of methylphenidate to children and youth, 1990-1996 Canadian Medical Association Journal (CMAJ) 2001, 165(11):1489-1494.
17. Criado Álvarez JJ Romo Barrientos C Variabilidad y tendencias en el consumo de metilfenidato en España. Estimación de la prevalencia del trastorno por déficit de atención con hiperactividad Revista de Neurología 2003, 37(9):806-810.
18. Donker GA Groenhof F van der Veen VJ Toenemend aantal voorschriften voor methylfenidaat in huisartspraktijen in Noordoost-Nederland, 1998-2003 Nederlands Tijdschrift voor Geneeskunde 2005, 30(31):1742-1747.
19. Department of Health Prescription Cost Analysis England 2005 London: National Health Service (NHS), Health and Social Care Information Centre, Health Care Statistics. Also previous issues, years 2006;p 1999-2005
20. Schwabe U Paffrath D Arzneiverordnungs-Report 2006 Berlin, Heidelberg, New York: Springer 2007 also previous issues, years 1993-2006
21. DeGrandpre R Ritalin Nation: Rapid-Fire-Culture and the Transformation of Human Consciousness New York, NY: Norton 2000
22. Perring C Medicating children: The case of Ritalin Bioethics 1997, 11(3-4):228-240. 10.1111/1467-8519.00061 11654776
23. Kociancic T Reed MD Findling RL Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children Expert Opinion on Drug Safety 2004, 3(2):93-100. 10.1517/ 14740338.3.2.93 15006715
24. Ekman JT Gustafsson PA Stimulants in AD/HD, a controversial treatment only in Sweden? European Child & Adolescent 2000, 9:312-313. 10.1007/ s007870070036
25. Foreman DM Foreman D Prendergast M Minty Is clinic prevalence of ICD-10 hyperkinesis underestimated? Impact of increasing awareness by a questionnaire screen in a UK clinic European Child & Adolescent Psychiatry 2001, 10(2):130-134. 10.1007/s007870170036 11469285
26. Schlander M Schwarz O Viapiano M Bonauer N Methylphenidate prescriptions for children and adolescents with attention-deficit/hyperactivity disorder (ADHD): New data from Nordbaden/Germany Value in Health 2006, 9(6):A191-192.
27. Llana ME Crismon ML Methylphenidate: Increased abuse or appropriate use? Journal of the American Pharmaceutical Association 1999, 39(4):526-530. 10467818
28. Wilens T Subtypes of ADHD at risk for substance abuse Presentation at the 157th Annual Meeting of the American Psychiatric Association; New York, NY: May 1-6, 2004
29. Graff Low K Gendaszek AE Illicit use of psychostimulants among college students: A preliminary study Psychology, Health & Medicine 2002, 7:283-287. 10.1080/13548500220139386
30. Trueman P Drummond M Hutton J Developing guidance for budget impact analysis Pharmacoeconomics 2001, 19(6):609-621. 10.2165/ 00019053-200119060-00001 11456210
31. Donohue JM Berndt ER Direct-to-consumer advertising and medication choice Journal of Public Policy & Marketing 2004, 23(2):. Fall 2004
32. Mizik N Jacobson R Are physicians "easy marks"? Quantifying the effects of detailing and sampling on new prescriptions Management Science 2004, 50(12):1704-1715. 10.1287/mnsc.1040.0281
33. Abikoff HG Hechtman L Klein RG Weiss G Fleiss K Etcovitch J Cousins L Greenfield B Martin D Pollack S Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment Journal of the American Academy of Child and Adolescent Psychiatry 2004, 43(7):802-811. 10.1097/01.chi.0000128791.10014.ac
34. Klein RG Abikoff HG Hechtman L Weiss G Design and rationale of controlled study of long-term methylphenidate and multimodal psychosocial treatment in children with ADHD Journal of the American 2004, 43(7):792-801.
35. MTA Cooperative Group A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder Archives of General Psychiatry 1999, 56:1073-1086. 10.1001/archpsyc.56.12.1073 10591283
36. MTA Cooperative Group Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: The multimodal treatment study of children with attention-deficit/hyperactivity disorder Archives of General Psychiatry 1999, 56:1088-1096. 10.1001/ archpsyc.56.12.1088 10591284
37. MTA Cooperative Group National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder Pediatrics 2004, 113(4):754-761. 10.1542/peds.113.4.754 15060224
38. Swanson JM Kraemer HC Hinshaw SP Arnold LE Conners CK Abikoff HB Clevenger W Davies M Elliott GR Greenhill LL Hechtman L Hoza B Jensen PS March JS Newcorn JH Owens EB Pelham WE Schiller E Severe JB Simpson S Vitiello B Wells K Wigal T Wu M Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment Journal of the American Academy of Child & Adolescent 2001, 40(2):168-179. 10.1097/ 00004583-200102000-00011
39. Medco Health Solutions Medco study reveals pediatric spending spike on drugs to treat behavioral problems Solutions Today May 18, 2004. http://www.drugtrend.com; last accessed June 15, 2005
40. Scrip Senator calls for a "comprehensive review" of ADHD drug risks Scrip World Pharmaceutical News 2006 3131 February 8, 2006 14
41. Scrip Cephalon's modafinil formulation for ADHD "approvable" in the US Scrip World Pharmaceutical News 2005 3101 October 25, 2005 27
42. Schlander M Budgetary Impact of Treatments for Attention-Deficit/ Hyperactivity Disorder (ADHD) in Germany: Increasing Relevance of Health Economic Evidence 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP), Berlin, August 22-26, 2004. Book of Abstracts, Steinkopff-Verlag, Darmstadt 2004 S-111-516, 187
43. Schlander M Vor der Ökonomisierung der ADHS-Therapie? Gesundheitsökonomische Aspekte Doch unzerstörbar ist mein Wesen∼ Diagnose AD(H)S - Schicksal oder Chance? Weinheim: Beltz Fitzner T, Stark W 2004:417-466.
44. Glaeske G Janhsen K GEK-Arzneimittel-Report 2006 Bremen, Schwaebisch-Gmuend, Schriftenreihe zur Gesundheitsanalyse 2006, 44.
45. Hack S Chow B Pediatric psychotropic medication compliance: A literature review and research-based suggestions for improving treatment compliance Journal of Child and Adolescent Psychopharmacology 2001, 11(19):59-67. 10.1089/104454601750143465
46. Swanson J Compliance with stimulants for attention-deficit/hyperactivity disorder. Issues and approaches for improvement CNS Drugs 2003, 17(2):117-131. 10.2165/00023210-200317020-00004 12521359
47. Schlander M Arzneimittelversorgung und Kostendaempfungspolitik: Perspektiven ein Jahr nach dem GMG Medizinische Klinik 2005, 100(6):314-324. 10.1007/s00063-005-1040-2 15968483
48. Makridakis S Wheelwright SC Hyndman RJ Forecasting - Methods and Applications New York, NY: Wiley 3 1998.
49. InnoVal-HC New products in development for treatment of ADHD: Literature review, Scrip and Pharmalive database analysis and interpretation Aschaffenburg, Germany: Institute for Innovation & Valuation in Health Care, data on file 2006.
50. Anderson VR Scott LJ Methylphenidate transdermal system in attention-deficit hyperactivity disorder in children Drugs 2006, 66(8):1117-1126. 10.2165/00003495-200666080-00007 16789796
51. McGough JJ Wigal SB Abikoff H Turnbow JM Posner K Moon E A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD Journal of Attention Disorders 2006, 9(3):476-485. 10.1177/1087054705284089 16481664
52. McGough JJ Pataki CS Suddath R Dexmethylphenidate extended-release capsules for attention-deficit/hyperactivity disorder Expert Review of Neurotherapeutics 2005, 5(4):437-441. 10.1586/14737175.5.4.437 16026226
53. Wigal S Swanson JM Feifel D Sangal RB Elia J Casat CD Zeldis JB Conners CK A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder Journal of the American Academy of Child & Adolescent Psychiatry 2004, 43(11):1406-1414. 10.1097/01.chi.0000138351.98604.92
54. Rosack J Regulatory and Legal Briefs Psychiatry News 2006, 41(2):30.
55. Ballon JS Feifel D A systematic review of modafinil: Potential clinical uses and mechanisms of action Journal of Clinical Psychiatry 2006, 67(4):554-566. 16669720
56. Turner D A review of the use of modafinil for attention-deficit hyperactivity disorder Expert Review of Neurotherapeutics 2006, 6(4):455-468. 10.1586/14737175.6.4.455 16623645
57. Waxmonsky JG Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults Essential Psychopharmacology 2005, 6(5):262-276. 16222911
58. Steinhoff K Attention-deficit/hyperactivity disorder: Medication treatment-dosing and duration of action American Journal of Managed 2004, 10(4);S99-S106.
59. Biederman J Swanson JM Wigal SB Kratochvil CJ Boellner SW Earl CQ Jiang J Greenhill L Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study Pediatrics 2005, 116(6):e777-e784. 10.1542/peds.2005-0617 16322134
60. Swanson JM Greenhill LL Lopez FA Sedillo A Earl CQ Jiang JG Biederman J Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: Results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation Journal of Clinical Psychiatry 2006, 67(1):137-147. 16426100
61. Scrip Cephalon drops Sparlon for attention deficit hyperactivity disorder after FDA rejection Scrip World Pharmaceutical News 200,6 3183 August 10, 2006 :21.
62. Remschmidt H by the Global ADHD Working Group Global consensus on ADHD/ HKD European Child & Adolescent Psychiatry 2005, 14(3):127-137. 10.1007/s00787-005-0439-x 15959658
63. Schlander M Long-Acting Medications for the Hyperkinetic Disorders: A Note on Cost-Effectiveness European Child & Adolescent Psychiatry 2007. March 30, 2007
64. Kola I Landis J Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery 2004, 3(8):711-715. 10.1038/nrd1470 15286737
65. Goodwin P Wright G Decision Analysis for Management Judgment Chichester, England: John Wiley & Sons 3 2004.
66. Matza LS Paramore C Prasad M A review of the economic burden of ADHD Cost effectiveness and Resource Allocation 2005, 3:5. 10.1186/ 1478-7547-3-5
67. Drummond MF Sculpher MJ Torrance GW O'Brien BJ Stoddart GL Methods for the economic evaluation of health care programmes Oxford: Oxford University Press 3 2005.
68. Romeo R Byford S Knapp M Annotation: Economic evaluations of child and adolescent mental health interventions: A systematic review Journal of Child Psychology and Psychiatry 2005, 46(9):919-930. 10.1111/ j.1469-7610.2005.00407.x
69. Jensen PS Garcia JA Glied S Crowe M Foster M Schlander M Hinshaw S Vitiello B Arnold LE Elliott G Hechtman L Newcorn JH Pelham WE Swanson J Wells K Cost-effectiveness of ADHD treatments: Findings from the multimodal treatment study of children with ADHD American 2005, 162(9):1628-1636.
70. Schlander M Cost-effectiveness of treatment options for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents: What have we learnt? 17th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP), Melbourne, September 10-14, 2006. Book of Abstracts, 43 (Abstract No. 2040) http://www.michaelschlander.com
71. Schlander M Schwarz O Hakkaart-van Roijen L Jensen PS Persson U Santosh P Trott GE the MTA Cooperative Group Cost-Effectiveness of Clinically Proven Treatment Strategies for Attention-Deficit/Hyperactivity Disorder (ADHD) in the United States, Germany, The Netherlands, Sweden, and United Kingdom Value in Health 2006, 9(6):A312.
72. Schlander M Cost-effectiveness of ADHD treatment strategies: What we do know... and what we do not know... 13th International Congress of the European Society for Child and Adolescent Psychiatry (ESCAP), Florence, August 26, 2007 http://www.michaelschlander.com
73. Schlander M Schwarz O Viapiano M Bonauer N Off-label utilization of methylphenidate for adults with attention-deficit/hyperactivity disorder: Insights from the Nordbaden project Value in Health 2006, 9(6):A311.
74. Schlander M Schwarz O Trott GE Viapiano M Bonauer N Who cares for patients with attention-deficit/hyperactivity disorder (ADHD)? Insights from Nordbaden (Germany) European Child and Adolescent Psychiatry 2007. April 28, 2007
75. Joint Formulary Committee British National Formulary (BNF) London: British Medical Association/Royal Pharmaceutical Society of Great Britain, March 2006 51 2006.
76. Gelbe Liste Pharmindex http://www.gelbe-liste.de Last accessed July 1, 2006
77. Office for National Statistics (ONS), London, England http://www.statistics.gov.uk
78. Statistisches Bundesamt, Wiesbaden, Germany http://www.destatis.de
79. American Psychiatric Association Diagnostic and statistical manual of mental disorders (DSM-IV) American Psychiatric Association, Washington, DC 4 1994.
80. World Health Organization International statistical classification of diseases and related health problems (ICD-10) Geneva, Switzerland: The World Health Organization 10 1992.
81. Taylor E Doepfner M Sergeant J Asherson P Banaschewski T Buitelaar J Coghill D Danckaerts M Rothenberger A Sonuga-Barke E Steinhausen H-C Zuddas A European guidelines for hyperkinetic disorder - first upgrade European Child & Adolescent Psychiatry 2004, 13(Suppl 1):7-30.
82. Faraone SV Sergeant J Gillberg C Biederman J The worldwide prevalence of ADHD: Is it an American condition? World Psychiatry 2003, 2(2):104-113. 1525089 16946911
83. Green M Wong M Atkins D Diagnosis and treatment of attention-deficit/ hyperactivity disorder in children and adolescents Technical Review No 3. Rockville, MD: Agency for Health Care Policy and Research, AHCPR Publication No 99-0050 1999.
84. Bruehl B Doepfner M Lehmkuhl G Der Fremdbeurteilungsbogen fuer hyperkinetische Stoerungen (FBB-HKS) - Praevalenz hyperkinetischer Stoerungen im Elternurteil und psychometrische Kriterien Kindheit und Entwicklung 2000, 9:115-125.
85. Ford T Goodman R Melltzer H The British Child and Adolescent Mental Health Survey 1999: The prevalence of DSM-IV disorders Journal of the American Academy of Child and Adolescent 2003, 42(10):1203-1211. 10.1097/ 00004583-200310000-00011
86. Koester I Schubert I Doepfner M Adam C Ihle P Lehmkuhl G Hyperkinetische Stoerungen bei Kindern und Jugendlichen: Zur Haeufigkeit des Behandlungsanlasses in der ambulanten Versorgung nach den Daten der Versichertenstichprobe AOK Hessen/KV Hessen Zeitschrift fuer Kinder- und Jugendpsychiatrie und Psychotherapie 2004, 32:157-166. 10.1024/ 1422-4917.32.3.157
87. Ferber Lv Lehmkuhl G Koester I Doepfner M Schubert I Froelich J Ihle P Methylphenidatgebrauch in Deutschland: Versichertenbezogene epidemiologische Studie ueber die Entwicklung von 1998 bis 2000 Deutsches Aerzteblatt 2003, 100:A41-A46.
88. Schubert I Koester I Adam C Ihle P Ferber Lv Lehmkuhl G Hyperkinetische Stoerung als Krankenscheindiagnose bei Kindern und Jugendlichen - eine versorgungsepidemiologische Studie auf der Basis der Versichertenstichprobe KV Hessen/AOK Hessen. Abschlussbericht an das Bundesministerium fuer Gesundheit und soziale Sicherung University of Cologne, Cologne, Germany 2002.
89. Schlander M Schwarz O Viapiano M Bonauer N Methylphenidate prescriptions for children and adolescents with attention-deficit/hyperactivity disorder (ADHD): New data from Nordbaden, Germany Value in Health 2006, 9(6):A191-A192.
90. Schubert I Selke GW Osswald-Huang P-H Schroeder H Nink K Methylphenidat-Verordnungsanalyse auf der Basis von GKV-Daten Wissenschaftliches Institut der AOK (WidO), Bonn, Germany 2002.
91. Michelson D Faries D Wernicke J Kelsey D Kendrick K Sally RS Spencer T the Atomoxetine ADHD Study Group Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study Pediatrics 2001, 108(5):1-9. 10.1542/peds.108.5.e83 11433046
92. Spencer T Heiligenstein JH Biederman J Faries D Kratochvil CJ Conners CK Potter WZ Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder Journal of Clinical Psychiatry 2002, 63(12):1140-1147. 12523874
93. Marcus SC Wan GJ Kemner JE Olfson M Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder Archives of Pediatrics & Adolescent Medicine 2005, 159:572-578. 10.1001/ archpedi.159.6.572 15939858
94. Sanchez RJ Crismon ML Barner JC Bettinger T Wilson J Assessment of adherence measures with different stimulants among children and adolescents Pharmacotherapy 2000, 25(7):909-917. 10.1592/ phco.2005.25.7.909
95. Kanavos P Policy approaches to pharmaceutical pricing and reimbursement in European countries London: London School of Economics, unpublished manuscript 2006.
96. Kassenaerztliche Vereinigung Baden-Wuerttemberg Verordnungsdaten 2004 Personal communication 2006.
97. InnoVal-HC Website http://www.innoval-hc.com/